Table 4.
Number of unusual residues in FDA approved antibodies derived from transgenic animals.
| International non- proprietary name | Target; Format | unusual residues | |
|---|---|---|---|
| Heavy chain | Light chain | ||
| Panitumumab | EGFR; Human IgG2 | 1 | 0 |
| Denosumab | RANK-L; Human IgG2 | 0 | 1 |
| Evolocumab | PCSK9; Human IgG2 | 4 | 2 |
| Brodalumab | IL-17R; Human IgG2 | 0 | 0 |
| Erenumab | CGRP receptor; Human IgG2 | 3 | 1 |
| Nivolumab | PD1; Human IgG4 | 3 | 0 |
| Dupilumab | IL-4R α; Human IgG4 | 1 | 2 |
| Ustekinumab | IL-12/23; Human IgG1 | 2 | 3 |
| Canakinumab | IL-1β; Human IgG1 | 2 | 3 |
| Golimumab | TNF; Human IgG1 | 0 | 0 |
| Ofatumumab | CD20; Human IgG1 | 1 | 0 |
| Ipilimumab | CTLA-4; Human IgG1 | 1 | 1 |
| Secukinumab | IL-17a; Human IgG1 | 1 | 1 |
| Alirocumab | PCSK9; Human IgG1 | 2 | 1 |
| Daratumumab | CD38; Human IgG1 | 0 | 0 |
| Olaratumab | PDGFRα; Human IgG1 | 4 | 0 |
| Bezlotoxumab | Clostridium difficile enterotoxin B; Human IgG1 | 3 | 0 |
| Sarilumab | IL-6R; Human IgG1 | 1 | 1 |
| Durvalumab | PD-L1; Human IgG1 | 0 | 1 |
| Burosumab | FGF23; Human IgG1 | 1 | 1 |
| Cemiplimab | PD-1; Human mAb | 1 | 7 |